Napredna pretraga

Pregled bibliografske jedinice broj: 864284

Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease


Babić Leko, Mirjana; Borovečki, Fran; Dejanović, Nenad; Hof, Patrick R.; Šimić, Goran
Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease // Neurologia Croatica / Šimić, Goran ; Mimica, Ninoslav (ur.).
Tučepi: Denona d.o.o., 2016. str. 94-94 (poster, domaća recenzija, sažetak, znanstveni)


Naslov
Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease

Autori
Babić Leko, Mirjana ; Borovečki, Fran ; Dejanović, Nenad ; Hof, Patrick R. ; Šimić, Goran

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Neurologia Croatica / Šimić, Goran ; Mimica, Ninoslav - Tučepi : Denona d.o.o., 2016, 94-94

Skup
Croatian Congress on Alzheimer's Disease (CROCAD- 16)

Mjesto i datum
Tučepi, Hrvatska, 05-08.10.2016.

Vrsta sudjelovanja
Poster

Vrsta recenzije
Domaća recenzija

Ključne riječi
VILIP-1 ; Alzheimer’s disease ; cerebrospinal fluid

Sažetak
Visinin-like protein 1 (VILIP-1) has become very important in past few years as a potential new biomarker of Alzheimer’s disease (AD). This neuronal calcium sensor protein, previously used as a marker of acute ischemic stroke is elevated in cerebrospinal fluid (CSF) of AD patients. The main goal of this study was to test CSF VILIP-1 potential in early AD diagnosis (in patients with mild cognitive impairment ; MCI), differentiation of AD from other primary causes of dementia, and in prediction of cognitive deterioration in AD. VILIP-1 levels were compared with three core (t-tau, Aβ1-42 and p-tau181) and, for the first time, with two additional CSF AD biomarkers (p- tau199 and p-tau231). VILIP-1 successfully differentiated two MCI groups of patients with and without pathological levels of all CSF biomarkers, except for t-tau. VILIP-1/Aβ1-42 and VILIP-1/p-tau231 ratios reached high sensitivities (above 70%) and specificities (above 85%) in differentiating AD patients from healthy controls. Additionally, VILIP-1 differentiated AD from patients with Lewy body disease with 77.1% sensitivity and 100% specificity. Thus, we propose VILIP-1 alone or/and in combination with other CSF biomarkers as a valuable addition to other biomarkers in early diagnosis of AD and in differentiation of AD from LBD. This work was supported by the Croatian Science Foundation grant. no. IP-2014- 09-9730.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Projekt / tema
IP-2014-09-9730

Ustanove
Medicinski fakultet, Zagreb